KEYTRUDA® (pembrolizumab) KEYNOTE-826 clinical data presentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

PDF, 2.66 MB

The KEYNOTE-826 study explores KEYTRUDA (pembrolizumab) in combination with chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer, whose tumours express PD‑L1 with a CPS ≥1.

CPS = Combined Positive Score; PD-L1 = Programmed Death Ligand 1

More information about KEYTRUDA® (pembrolizumab) in cervical cancer

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.